FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789891109> ?p ?o ?g. }

• W2789891109 abstract "Background: Neoadjuvant endocrine therapy (NET) is gaining more acceptances for the management of estrogen receptor (ER) positive breast cancer (BC). Rate of patients achieving pathological complete response is very low and Ki67 suppression and PEPI score are the only prognostic factors associated with relapse free survival. The aim of our study was to identify biomarkers of prediction of distant relapse risk that could help clinicians in the decision-making of systemic adjuvant treatment in patients previously treated with NET Material & Methods: Retrospective study of 119 postmenopausal women with ER or progesterone receptor (PR) positive BC treated with NET in ICO-HUB from 1997 to 2009. Clinical-pathological data and treatments administered were reviewed. IHC expression of ER, PR, Ki67, Androgen receptor (AR), BCL-2, Cyclin D1 (CD1), p16, p53, CD 44 and synaptophysin were analyzed in post-NET surgical formalin-fixed paraffin-embedded tumor samples through a tissue microarray. Survival was calculated by Kaplan-Meier method. Univariate and multivariate analysis of variables associated with distant relapse free survival (DRFS) was evaluated by Cox proportional hazard model. Results: Mean age was 74 (63-88). cT: T2 5%, T3 6.5%, T4 43.5%. cN: N0 59%, N1 25%, N2-3 16%. Stage: I 21%, II 49.5%, III 29.5%. Histological subtype: ductal 84%, lobular 6%, others 10%. Histological grade: G1 20%, G2 55%, G3 25%. Vascular invasion 15%. NET: Aromatase Inhibitors 64%, SERM 36%. Median duration of NET 8.5 months. Clinical Response: Complete 4%, Partial 55%, Stable 37%, Progression 4%. Surgery: Lumpectomy 72%, Mastectomy 28%;Lymphadenectomy 70.5%, Sentinel lymph node biopsy 6%, No surgical approach of axilla 23.5%. Surgical specimen: ypT1 36%, ypT2 54%, ypT3 6%, ypT4 4%; ypN0 28%, ypN1 22%, ypN2 13.5%, ypN3 12% ypNx 23.5%. Surgical margins: Negative 89% Positive 11%. Median fibrosis rate 20% (0-95). PR and Ki67 showed a statistically significant decrease after NET(p Adjuvant treatment: chemotherapy 7%, radiotherapy 76%, endocrine therapy 96%. Median follow-up: 104 months. Only 21 patients developed distance relapse. Median OS was 139 months [95% CI = 98-181]. Univariate analysis for DRFS showed statistically significant differences in cN (HR=3), histological grade 3 (HR=3.61), ypN (HR=3.62), p16 (HR=6.1) and p53 (HR=2.79). Multivariate analysis of post-NET biomarkers showed that negative nuclear p16 expression (HR=4.79)and positive p53 (HR=2.83)were independently associated with worse DRFS. In multivariate analysis of all clinico-pathological and molecular factors, histological grade 3 (HR=2.82) was the sole DRFS independent factor. Conclusions: Negative nuclear p16 expression and positive p53 post-NET were associated with worseDRFS. Whenall clinico-pathological and molecular factors were analysed, G3 was the sole DRFS independent factor. Patients with G3, negative p16 or positive p53 after NET could probably benefit from adjuvant chemotherapy or CDK 4-6 inhibitors treatment. In our series, we did not find usefulness in analysing ER, PR and Ki67 post-NET changes to predict DRFS. Citation Format: Gil-Gil M, Morilla I, Petit A, Soler T, Perez-Martin X, Guma A, Pla MJ, Ortega R, Garcia-Tejedor A, Falo C, Montal R, Perez-Casanova L, Loayza C, Pernas S. Biomarkers to predict distant recurrence free survival after neoadjuvant endocrine therapy in breast cancer. A long follow up retrospective study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-08-08." @default.
• W2789891109 created "2018-03-29" @default.
• W2789891109 creator A5006949449 @default.
• W2789891109 creator A5007113784 @default.
• W2789891109 creator A5013236445 @default.
• W2789891109 creator A5024715423 @default.
• W2789891109 creator A5028384284 @default.
• W2789891109 creator A5031187796 @default.
• W2789891109 creator A5042670578 @default.
• W2789891109 creator A5046274506 @default.
• W2789891109 creator A5046771310 @default.
• W2789891109 creator A5047355721 @default.
• W2789891109 creator A5059890986 @default.
• W2789891109 creator A5071763441 @default.
• W2789891109 creator A5073702608 @default.
• W2789891109 creator A5079951246 @default.
• W2789891109 date "2018-02-14" @default.
• W2789891109 modified "2023-10-18" @default.
• W2789891109 title "Abstract P4-08-08: Biomarkers to predict distant recurrence free survival after neoadjuvant endocrine therapy in breast cancer. A long follow up retrospective study" @default.
• W2789891109 doi "https://doi.org/10.1158/1538-7445.sabcs17-p4-08-08" @default.
• W2789891109 hasPublicationYear "2018" @default.
• W2789891109 type Work @default.
• W2789891109 sameAs 2789891109 @default.
• W2789891109 citedByCount "0" @default.
• W2789891109 crossrefType "proceedings-article" @default.
• W2789891109 hasAuthorship W2789891109A5006949449 @default.
• W2789891109 hasAuthorship W2789891109A5007113784 @default.
• W2789891109 hasAuthorship W2789891109A5013236445 @default.
• W2789891109 hasAuthorship W2789891109A5024715423 @default.
• W2789891109 hasAuthorship W2789891109A5028384284 @default.
• W2789891109 hasAuthorship W2789891109A5031187796 @default.
• W2789891109 hasAuthorship W2789891109A5042670578 @default.
• W2789891109 hasAuthorship W2789891109A5046274506 @default.
• W2789891109 hasAuthorship W2789891109A5046771310 @default.
• W2789891109 hasAuthorship W2789891109A5047355721 @default.
• W2789891109 hasAuthorship W2789891109A5059890986 @default.
• W2789891109 hasAuthorship W2789891109A5071763441 @default.
• W2789891109 hasAuthorship W2789891109A5073702608 @default.
• W2789891109 hasAuthorship W2789891109A5079951246 @default.
• W2789891109 hasConcept C121608353 @default.
• W2789891109 hasConcept C126322002 @default.
• W2789891109 hasConcept C143998085 @default.
• W2789891109 hasConcept C167135981 @default.
• W2789891109 hasConcept C207103383 @default.
• W2789891109 hasConcept C2776694085 @default.
• W2789891109 hasConcept C2777757722 @default.
• W2789891109 hasConcept C2777982462 @default.
• W2789891109 hasConcept C2778292576 @default.
• W2789891109 hasConcept C2778311097 @default.
• W2789891109 hasConcept C2779572924 @default.
• W2789891109 hasConcept C2780739268 @default.
• W2789891109 hasConcept C44249647 @default.
• W2789891109 hasConcept C50382708 @default.
• W2789891109 hasConcept C530470458 @default.
• W2789891109 hasConcept C71924100 @default.
• W2789891109 hasConceptScore W2789891109C121608353 @default.
• W2789891109 hasConceptScore W2789891109C126322002 @default.
• W2789891109 hasConceptScore W2789891109C143998085 @default.
• W2789891109 hasConceptScore W2789891109C167135981 @default.
• W2789891109 hasConceptScore W2789891109C207103383 @default.
• W2789891109 hasConceptScore W2789891109C2776694085 @default.
• W2789891109 hasConceptScore W2789891109C2777757722 @default.
• W2789891109 hasConceptScore W2789891109C2777982462 @default.
• W2789891109 hasConceptScore W2789891109C2778292576 @default.
• W2789891109 hasConceptScore W2789891109C2778311097 @default.
• W2789891109 hasConceptScore W2789891109C2779572924 @default.
• W2789891109 hasConceptScore W2789891109C2780739268 @default.
• W2789891109 hasConceptScore W2789891109C44249647 @default.
• W2789891109 hasConceptScore W2789891109C50382708 @default.
• W2789891109 hasConceptScore W2789891109C530470458 @default.
• W2789891109 hasConceptScore W2789891109C71924100 @default.
• W2789891109 hasLocation W27898911091 @default.
• W2789891109 hasOpenAccess W2789891109 @default.
• W2789891109 hasPrimaryLocation W27898911091 @default.
• W2789891109 isParatext "false" @default.
• W2789891109 isRetracted "false" @default.
• W2789891109 magId "2789891109" @default.
• W2789891109 workType "article" @default.